The in vitro antibacterial effects of cefoxitin, a semisynthetic cephamycin, cefuroxime, a new cephalosporin antibiotic, and cephaloridine were compared. With gram-positive bacteria, marked differences were found only in the effects against Streptococcus faecalis, where cephaloridine and cefuroxime were superior to cefoxitin. With gram-negative aerobic bacteria, cefoxitin, which is known to be more resistant to beta-lactamases from gram-negative bacteria than any cephalosporin, was found to be more effective than cefuroxime and cephaloridine against ampicillin-resistant strains of Escherichia coli and indole-positive strains of Proteus. Haemophilus influenzae was found to be more susceptible to cefuroxime than to cefoxitin and cephaloridine. When ampicillin-resistant strains of H. influenzae were tested, markedly higher minimal inhibitory concentration values were obtained with cephaloridine in comparison to those obtained with ampicillin-susceptible strains. These increases in the minimal inhibitory concentration values were not observed with cefoxitin and cefuroxime, probably due to the resistance of these two compounds to beta-lactamases. Strains ofBacteroides fragilis were found to be much more susceptible to cefoxitin than to cefuroxime, which in turn was superior to cephaloridine. The results obtained indicate that cefoxitin and cefuroxime both are superior in their antibacterial spectra to the cephalosporins that are now in clinical use.
Since the introduction of cephalothin and cephaloridine as the first clinically available cephalosporins, a large number of new cephalosporins have been synthesized and are now in routine use. Most of these new compounds have only minor advantages over cephalothin and cephaloridine as regards antibacterial activity. It is therefore of considerable interest that cefoxitin and cefuroxime, two new compounds presently undergoing clinical trials, seem to have markedly broader antibacterial spectra than any of the cephalosporins in clinical use (1, 6, 6a, 7a, 10, 12) . It should be noted that, although cefuroxime [-6R, 7R-3-carbamoyloxymethyl -7 -(2Z) -2 -methoximino(fur -2 -yl) -acetamidoceph-3-em-4-carboxylate] is a cephalosporin, synthesized from cephalosporin C, cefoxitin is a cephamycin, derived from cephamycin C (Fig. 1 ). Cephamycins differ from cephalosporins especially by a 7-alpha-methoxy group.
In this study the antibacterial activities of cefoxitin and cefuroxime were compared to each other and to that of cephaloridine.
MATERIALS AND METHODS
Bacterial strains. All strains tested were recent clinical isolates. Thirty-two strains of Haemophilus influenzae from patients with upper-respiratorytract diseases were used. Six of the strains were ampicillin resistant. Thirty-five indole-positive and 32 indole-negative strains of Proteus spp., all isolated from patients with urinary tract infections, were employed. Sixty-one strains of Escherichia coli, 36 from blood cultures and 25 from patients with urinary tract infections, were also included in the study. The latter strains were all characterized by transferable multiple antibiotic resistance and were considered as R factor bearing (R+). Of these strains 12 were completely resistant to ampicillin as determined by a disk test (3) . Two of the strains from the blood cultures were found to be ampicillin resistant. Other strains employed were: 27 strains of Bacteroides fragilis, obtained from patients with various forms of deep-seated infections, 20 strains of type A and 16 strains of type B Neisseria meningitidis, all isolated from patients with clinically manifest meningococcal infections; 36 strains of Streptococcus faecalis, isolated from patients with urinary tract infections; 32 strains of Streptococcus pneumoniae, from patients with upper and lower respiratory tract infections; and 36 beta-lactamase-producing strains of Staphylococcus aureus, obtained from patients with various forms of staphylococcal infection.
Media. The antibiotic susceptibility studies were in most cases performed on the ASM medium described by Wretlind et al. (13) . Rabbit blood (8%) and IsoVitaleX (2%, BBL) were added to the ASM me- dium when strains of meningococci, pneumococci, Haemophilus, and Bacteroides were tested. The medium was chocolatized before inoculation with H. influenzae, pneumococci, and meningococci. When the Proteus strains were tested, a cysteine-lactoseelectrolyte-deficient agar (Oxoid) was used.
Antibiotics. Cefoxitin (Mefoxin, Merck, Sharpe & Dome Research Laboratories), cefuroxime (Glaxo Research Ltd.) and cephaloridine (Ceporan, Glaxo) were all used as freshly prepared solutions of dry substance in saline.
Determinations of MIC. The agar dilution technique described by Ericsson and Sherris (3) was used for the determination of minimal inhibitory concentrations (MIC). The bacterial inocula consisted of 4- h nutrient broth cultures diluted in saline to give a concentration of 5 x 104 bacteria/ml (in some experiments, 5 x 105/ml). Aliquots of 0.001 ml were inoculated on the agar plates using a slight modification of the device described by Steers et al. (8) . After incubation at 37 C for 18 h the plates were read, and the concentrations of antibiotics giving 100% or 50 to 90% inhibition of bacterial growth were determined. When the B. fragilis strains were tested, incubation in 95% H2-5% CO2 was used.
RESULTS
The accumulated percentages of bacterial strains completely inhibited by the various antibiotics tested are presented in Fig. 2 .
Effect on gram-positive bacteria. The MIC of cefuroxime and cephaloridine against grampositive bacteria tended to be lower than the MICs of cefoxitin. This was most pronounced against strains of S. faecalis. Of the 37 strains tested, only 3 were inhibited by 128 ,ug of cefoxitin per ml, whereas all strains were inhibited by MICs of less than 16 jig of cephaloridine or cefuroxime per ml. On penicillinase-producing staphylococci, cephaloridine was found to be more active than either cefuroxime or cefoxitin.
Effect on gram-negative bacteria. Against E. coli no differences between the compounds were noted when the MICs for all strains were VOL. 9, 1976 Table 1 demonstrates, however, that there seems to be a better antibacterial effect produced by cefoxitin on ampicillin-resistant strains of E. coli than by cefuroxime, which in turn was superior to cephaloridine. The same tendency was observed with indole-positive Proteus strains, which were all inactivated by 8 ,ug of cefoxitin per ml, whereas the MICs were above 16 ,g/ml for 28% of the strains when cephaloridine was tested and for 54% of the strains when cefuroxime was tested. Against indole-negative strains of Proteus, cephaloridine seemed more effective than either cefoxitin or cefuroxime.
H. influenzae was found to be more susceptible to cefuroxime than to cephaloridine or cefoxitin. Six of the Haemophilus strains tested were ampicillin resistant, and these strains were most susceptible to cefuroxime, whereas cephaloridine was found to be inferior to cefoxitin.
Against meningococci both cephaloridine and cefuroxime inactivated all strains at concentrations below 0.5 pug/ml, whereas a concentration of 2 to 4 ug of cefoxitin per ml was required to inactivate all strains.
Cefoxitin was found to be effective against the strains ofB. fragilis tested. Cefuroxime and cephaloridine were both less active against Bacteroides. To study the importance of the size ofthe inoculum, it was increased 10-fold with 11 of the B. fragilis strains. This did not affect the MIC values obtained with cefoxitin, whereas considerable increases were noted with cefuroxime and even more so with cephaloridine (Table   2) . DISCUSSION
The antibacterial activity of the clinically used cephalosporins is characterized by low Cefoxitin, which is not a cephalosporin but a cephamycin, has been found to be much more resistant to gram-negative beta-lactamases than cephalosporins and also to have a remarkably good effect on B. fragilis (1, 6, 7, 10, 12) . Cefuroxime, which was synthesized later than cefoxitin and which is a cephalosporin, has been found to be more beta-lactamase resistant than other cephalosporins and, in addition, to have a better antibacterial effect on some gram-negative bacteria, such as H. influenzae and meningococci (2, 9). The present study presents evidence of the superior antibacterial effect of cefoxitin on indole-positiveProteus andB. fragilis compared to cefuroxime and cephaloridine. These differ- influenzae between cefuroxime and cefoxitin were not restricted to the ampicillin-susceptible strains but were also observed when ampicillin-resistant, beta-lactamase-producing strains were tested. This finding indicates that cefuroxime is equally or more resistant to the beta-lactamases produced by H. influenzae than is cefoxitin. Cephaloridine was found to have a better antibacterial effect than cefoxitin against gram-positive bacteria, and it was also superior to cefuroxime in its effect on penicillinase-producing S. aureus. On gram-negative bacteria cephaloridine seemed to be less effective than the other two compounds, with the exception of indole-negative Proteus spp. The results obtained with cephaloridine were in agreement with earlier studies (4, 9, 11) .
Pending the availability of further clinical and pharmacokinetic data on cefoxitin and cefuroxime, it is not possible to predict the clinical usefulness of these two compounds compared to the commercially available cephalosporins. The antibacterial spectra of these two new compounds do, however, indicate that they might become the two most important members of the cephalosporin group.
